Last updated: 11/27/2018 21:10:26

Meta analyses on pregnancy outcomes with respect to the effect of Herpes Simplex Virus (HSV) antigen and of the adjuvant (AS04)

GSK study ID
HSV Meta analyses
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Meta analyses on pregnancy outcomes with respect to the effect of Herpes Simplex Virus (HSV) antigen and of the adjuvant (AS04)
Trial description: The aim of this meta analyses on pregnancy outcomes was to assess the effect of HSV antigen and of the adjuvant AS04 on spontaneous abortion, as requested by GSK Vaccine Safety Monitoring Board (VSMB).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Relative risk assessment for the percentage of subjects with first pregnancy in the vaccination exposure window leading to spontaneous abortion

Timeframe: Not Applicable

Secondary outcomes:

Relative risk assessment for the percentage of subjects with first pregnancy leading to spontaneous abortion

Timeframe: Not Applicable

Relative risk assessment for the percentage of subjects with first pregnancy leading to elective termination

Timeframe: Not Applicable

Relative risk assessment for the percentage of subjects with first pregnancy the vaccination exposure window leading to elective termination

Timeframe: Not Applicable

Relative risk assessment for the percentage of subjects with pregnancy

Timeframe: Not Applicable

Interventions:
Other: Data Collection
Enrollment:
20985
Observational study model:
Cohort
Primary completion date:
2010-01-09
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Herpes Simplex Virus
Product
Herpes Simplex Vaccine
Collaborators
Not applicable
Study date(s)
September 2010 to September 2010
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female
Age
13 - 45 Year
Accepts healthy volunteers
yes
  • All interventional GSK sponsored studies within HSV prophylactic clinical development that were completed before Sept 2010.
  • All females from the eligible studies.
  • Not applicable
Inclusion and exclusion criteria
Inclusion criteria:
  • All interventional GSK sponsored studies within HSV prophylactic clinical development that were completed before Sept 2010. All females from the eligible studies. Since the contribution of a study to the relative risk is contingent on the presence of the control group in the study and of at least one negative outcome, only studies meeting these conditions were used in the evaluation of relative risk.
Exclusion criteria:
  • Not applicable

Trial location(s)

No location data available.

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Finalized
Actual primary completion date
2010-01-09
Actual study completion date
2010-01-09

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website